medical | nksamr

AcuteMarketReports.com has announced the addition of “Outlook of Global and Chinese Medical Devices Industry 2015-2020 “Market Research Report to their Database.

Medical devices market is a scattered market in which hundreds of companies worldwide participate. The medical device market in terms of revenues is not even half as large as the global pharmaceutical market, though it sees many more transaction. Although the largest component of the market is in the U.S., the majority of sales are non-US, and growth is occurring in other markets. In the future couple years, the Chinese market size will remain on a steady growth trend by the increasing demands from downstream of medical devices industry. ASKCI predicts Chinese domestic medical devices market size will achieve RMB 419 billion by the end of 2020, and the revenues of medical devices manufacture industry could achieve RMB 43 billion.

View Full Report with TOC @ http://www.acutemarketreports.com/report/outlook-of-global-and-chinese-medical-devices-industry-2015-2020

List of Tables:

Table 1 Chinese classification of medical devices

Table 2 Regulations of Chinese medical devices industry

Table 3 Regulations of global medical devices industry

List of Figures:

Figure 1 HCA corporation: revenues, salary costs, bad debt

Figure 2 Net incomes, HCA and community health

Figure 3 Numbers of Hospitals in the US, 1975-2011

Request a sample of Report @ http://www.acutemarketreports.com/request-free-sample/48019

The Aim of this report:

To provide readers with comprehensive & in-depth understanding of global and Chinese medical devices industry;

To introduce major players of medical devices industry in the world;

To introduce major players of medical devices industry in China;

To disclose market size of both domestic and global medical devices industry;

To analyze global development trends of medical devices industry;

To analyze China’s development trends of medical devices industry;

To understand position of China’s medical devices industry in the world;

To reveal operation situation of China’s medical devices industry.

View all reports of this category @ http://www.acutemarketreports.com/category/medical-equipments-market

About Us:

Acute Market Reports is the most sufficient collection of market intelligence services online. It is your only source that can fulfill all your market research requirements. We provide online reports from over 100 best publishers and upgrade our collection regularly to offer you direct online access to the world’s most comprehensive and recent database with expert perceptions on worldwide industries, products, establishments and trends. Our database consists of 200,000+ market research reports with detailed & minute market research.

Contact info:

Chris Paul

Office No 01, 1st Floor,

Aditi Mall, Baner, Pune,

MH, 411045 India

Phone (India): +91 7755981103

Toll Free (US/Canada): +1-855-455-8662

Email: sales@acutemarketreports.com

Web: www.acutemarketreports.com

#medical

AcuteMarketReports.com has announced the addition of ” Frontier Pharma: Obesity – Identifying and Commercializing First-in-Class Innovation ” Market Research Report to their Database.

Obesity is a major growing health concern around the world. In most markets, a person is considered obese if their Body Mass Index (BMI) exceeds 30 kilograms per square meter (kg/m2), calculated by dividing body mass in kilograms by height in meters squared. With the global prevalence continuing to rise, the disease has placed significant burden on healthcare expenditure, as it is also a major risk factor for cardiovascular diseases, diabetes and cancer.

View Full Report with TOC @ http://www.acutemarketreports.com/report/frontier-pharma-obesity-identifying-and-commercializing-first-in-class-innovation

Anti-obesity pharmacotherapy can be used as an adjunct lifestyle modification to improve weight loss in order to significantly reduce obesity-associated health risks in obese patients. However, the use of currently available anti-obesity drugs is largely limited by poor long-term safety and a modest weight loss effect. Despite substantial clinical and regulatory challenges, the early-stage obesity pipeline remains robust, containing a high level of first-in-class innovation that has the potential to be translated into effective and safe weight loss treatments.

List of Figures and Tables:

Table 1: The International Classification of Underweight, Overweight and Obesity in Adults 13

Table 2: Treatment Options Dependent on Body Mass Index 15

Figure 1: Innovation Trends in Product Approvals, 1987–2013 5

Figure 2: Sales Performance of First-in-Class and Non-First-in-Class Products Post Marketing Approval, 2006–2013 7

Figure 3: Molecular Targets of Marketed Products, 2015 19

Figure 4: Developmental Pipeline Overview 23

Figure 5: Players in the Obesity Pipeline 24

Figure 6: Developmental Pipeline Overview 25

Figure 7: Molecular Target Category Comparison, Pipeline and Marketed Products 26

Figure 8: Molecular Target Category Comparison, Pipeline First-in-Class and Established Molecular Targets 28

Figure 9: Obesity, Global, First-in-Class Pipeline Products 29

Figure 10: Signaling Networks of Functional Families in Obesity 33

Figure 11: Location of Key First-in-Class Targets within the Signaling Matrix 34

Figure 12: First-in-Class Molecular Target Analysis Matrix 36…

Request a sample of Report @ http://www.acutemarketreports.com/request-free-sample/48776

Scope:

Historically, the obesity market has suffered from long-term safety concerns and modest efficacy with current treatments, both of which contribute to the low prescription rate and limited widespread use.

What are the main safety concerns that lead to significant challenges in gaining drug approval in obesity?

Why is sustainable weight loss difficult to achieve, and what is the implication for future drug development?

Analysis reveals a high level of innovation and diversity in the pipeline, with 75 first-in-class programs identified to act on 60 unique molecular targets.

What is the dominant target family across these first-in-class pipeline products?

How well do they align with the underlying signaling pathways governing the central and peripheral regulation of food intake, and energy expenditure?

Some first-in-class targets are deemed more likely to be developed into marketable treatments than others, having demonstrated substantial body weight reduction in

Preclinical studies and addressing multiple mechanisms underpinning the development of obesity…

View all reports of this category @ http://www.acutemarketreports.com/category/pharmaceutical-market